[Cost-effectiveness analysis of home administration versus hospital administration of intravenous immunoglobulin].
A prospective analysis was carried out to evaluate the cost-effectiveness of two alternatives for the treatment of hypo-agammaglobulinemia with intravenous immunoglobulin: the current hospital administration and the administration in the patient's home. 38 patients or relatives were surveyed about their personal or family characteristics, current therapy and the possibility to be treated at home. Home therapy is feasible--43% of the patients would be able to have it and would prefer it--and less costly, as costs could be reduced in 18-20%. This alternative is felt as a greater patient's independence, with less feeling of illness and preventing the loss of school or work hours. 32% prefer the hospital because they feel more secure in it.
Rodríguez
M
M
Facultad de Ciencias Económicas, Universidad de Barcelona.
Procupet
A
A
Heras
J
J
D000293:Adolescent; D000328:Adult; D003362:Cost-Benefit Analysis; D005260:Female; D006699:Home Care Services / Q000191:economics*; D006757:Hospital Units / Q000191:economics*; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D011446:Prospective Studies
D007136:Immunoglobulins
Análisis coste efectividad de la administración domiciliaria de inmunoglobulina intravenosa frente a su administración hospitalaria.